Emulate, Inc. announced today a published study in collaboration with Johns Hopkins University School of Medicine, that demonstrated superior functionality of the Duodenum Intestine-Chip populated with organoids, compared to organoids alone. The study, published in the peer-reviewed journal, eLife , showed that the Intestine-Chip produced a nearly identical global transcriptomic profile compared to human intestine duodenum tissue, whereas the signature from the organoids alone had significant differences from the human intestine tissue. The authors further showed that the similarities at the transcriptomic level also resulted in significantly more accurate physiological function of the Intestine-Chip compared to organoids alone. These results demonstrate the potential of the Intestine-Chip to provide a robust system to accurately recreate human intestine tissues for highly predictive and human-relevant preclinical drug assessment, including drug transport, metabolism, and drug-drug interactions.
In this research, Emulate scientists in collaboration with scientist at Johns Hopkins University School of Medicine established the Duodenum Intestine-Chip from organoids derived from endoscopic biopsies of healthy adult human donors and primary human intestinal microvascular endothelial cells derived from human small intestine. The Intestine-Chip recreated the barrier function and multilineage differentiation of adult human intestinal tissue. Global gene expression was assessed by RNA-sequencing analysis and showed that the profile of the Intestine-Chip and freshly isolated human adult duodenum tissue were remarkably similar; in contrast, the organoids alone from the same donor showed significant differences in RNA-sequencing analysis. Additionally, the biology for drug transporters and drug metabolizing enzymes of the intestine remained intact in the Duodenum Intestine-chip, which is not effectively modeled with current animal testing due to the species-specific nature of these drug transporters, drug metabolizing enzymes, and the factors regulating them.
Using our Intestine-Chip, we are able to accurately recreate key functions of the human duodenum. These findings show a path forward to using a more human-relevant and robust system to better predict pharmacokinetics and drug-drug interaction. Today, we see the value of using our Intestine-Chip product with organoids as a leading-edge preclinical testing method. Further in the future, we envision exciting potential applications for our Intestine-Chip to utilize cells isolated from individual patients to be used for personalized medicine." Geraldine A. Hamilton, President and Chief Scientific Officer of Emulate Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology